Intellectual Property & Proprietary Rights



Issued US Patents


US #6,153,182

Compositions and doses of lymphotactin given in conjunction with vaccines to provide improved immune response

US #6,479,047

Methods of lymphotactin use as an adjuvant to boost mucosal immune responses to a vaccine antigen

US #7,919,083

Antibodies or the use of antibodies directed against CCL25 and CCR9 that propagate melanoma growth, migration, and/or invasion.

US #7,964,194

Antibodies or the use of antibodies directed against CXCL10 that mediate inflammation

US #8,097,250

Antibodies or the use of antibodies directed against CXCL13 and CXCR5 that propagate melanoma growth, migration, and/or invasion

US #8,231,907

Methods of milling nanoparticles containing a biologically active agent, at least one biopolymer, where coating contains at least one polymer or ligand

US #8,318,170

Antibodies or the use of antibodies directed against CXCL9 and CXCL11 that mediate inflammation

US #8,512,701

Antibodies or the use of antibodies directed against CXCL13 and CXCR5 to prevent and treat cancer and cancer cell migration.

US #8,541,564

Novel chemokine-immunoglobulin fusion polypeptides and uses to treat chemokine receptor-mediated disorders, including cancer and inflammatory disorders.

US #8,580,261

Antibodies or the use of antibodies directed against CCL25 that mediate inflammation

US #8,563,476

Antibodies or the use of antibodies directed against chemokines (CXCL9, CXCL10, CXCL11, and CXCL13) and chemokine receptors (CXCR3 and CXCR5) as agents against inflammatory disorders

US #8,568,784

Compositions comprising milled nanoparticles containing an anti-cancer agent, polyethylene glycol, and starch, cellulose, collagen, lactose, or alginate

US #8,658,377

Antibodies or the use of antibodies directed against CCL25 and CCR9 to detect cancer and metastasis

US #8,796,422

CCL2-immunoglobulin fusion polypeptides and conjugates for targeted treatment of CCR2-and CCR4-mediated disorders

US #8,962,030

Methods of formulating a pharmaceutical composition using milled nanoparticles of precise size containing an anti-cancer agent, polyethylene glycol, and starch, cellulose, collagen, lactose, or alginate

US #8,987,210

Chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates

US #9,233,120

Antibodies or the use of antibodies directed against CCL25 and CCR9 to prevent and treat cancer and cancer cell migration

US #9,249,204

CXCL13-immunoglobulin fusion polypeptides and conjugates for targeted treatment of CXCR5-mediated disorders.

US #9,493,531

CCL18-immunoglobulin fusion polypeptides and conjugates for targeted treatment of PITPNM3-, GPR30-, and CCR8 -mediated disorders.

US #9,783,588

CXCL12-immunoglobulin fusion polypeptides and conjugates for targeted treatment of CXCR4-mediated disorders.

US20170280712A1 Notice of Allowance (6/28/2018)

Nanoformulations for plants.


Issued Foreign Patents


CN ZL201280032847.7

Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

EP2652508B1

The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer


Pending US Patents


US 12/967,795

Antibodies or the use of antibodies directed against CCL25 and CCR9 that propagate leukemia growth, migration, and/or invasion

US 12/967,816

Antibodies or the use of antibodies directed against CCL25 and CCR9 that propagate carcinoma growth, migration, and/or invasion

US 12/968,659

Antibodies or the use of antibodies directed against CXCL13 and CXCR5 that propagate carcinoma growth, migration, and/or invasion

US 12/968,698

Antibodies directed against CXCL13 and CXCR5 that propagate lymphoma growth, migration, and/or invasion

US 13/014,240

Antibodies or the use of antibodies directed against CCL25 and CCR9 that propagate lymphoma or myeloma growth, migration, and/or invasion

US 13/014,310

Antibodies or the use of antibodies directed against CXCL13 and CXCR5 that propagate leukemia and myeloma growth, migration, and/or invasion

US 13/104,654

Antibodies or the use of antibodies directed against chemokines (CXCL9) that mediate inflammation

US 13/105,335

Antibodies or the use of antibodies directed against chemokines (CCL25 and other CCL chemokines) that mediate inflammation

US 13/233,769

Antibodies or the use of antibodies directed against CXCL16 and CXCR6 to prevent and treat cancer and cancer cell migration

US 13/312,343

Antibodies or the use of antibodies directed against CXCL16 and CXCR6 to detect cancer and metastatic path

US 13/313,705

Antibodies or the use of antibodies directed against CXCL13 and CXCR5 to detect cancer and metastatic path

US 13/535,202

Antibodies or the use of antibodies directed against chemokines (CXCL9, CXCL10, CXCL11, and CXCL13) and chemokine receptors (CXCR3 and CXCR5) for inhibition of inflammation

US 13/569,941

Compositions and methods comprising milled nanoparticles for specific targeting and delivery of cytotoxic drugs to cancer cells

US 14/534,982

Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies

US 14/843,764

Methods for prevention and treatment of inflammation using anti-chemokine antibodies

US 14/843,811

Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation


Pending Foreign Patents


EP 2866830

Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation

JP 2015524793

Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation

CN 104870013

Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation

EP 2652506

The use anti-cxcl16 and anti-cxcr6 antibodies for the treatment or detecting cancer

JP 2014503063

The use anti-cxcl16 and anti-cxcr6 antibodies for the treatment or detecting cancer

CN 106093388

The use anti-cxcl16 and anti-cxcr6 antibodies for the treatment or detecting cancer

JP 2014505239

Use of anti cxcl13 and anti cxcr5 antibodies for the treatment or detection of cancer

CN 103608680

Use of anti cxcl13 and anti cxcr5 antibodies for the treatment or detection of cancer

EP 2652507

Detecting cancer with anti-ccl25 and anti-ccr9 antibodies

JP 2014501387

Detecting cancer with anti-ccl25 and anti-ccr9 antibodies

CN 103620411

Detecting cancer with anti-ccl25 and anti-ccr9 antibodies

EP 2651443

Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration

JP 2014508117

Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration

CN 103619351

Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration

EP 2714065

Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

JP 2014518632

Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

CN 208180054247 / HK 14111652

Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

EP 2744483

Delivery system for specifically targeting cancer cells and method of use thereof

JP 2014521743

Delivery system for specifically targeting cancer cells and method of use thereof

CN 104066425 / HK 151002888.4

Delivery system for specifically targeting cancer cells and method of use thereof